Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)

• Status: Completed
• Trial end date: 2008-04-08
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the effectiveness of rizatriptan benzoate in the early treatment of an acute migraine attack.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Rizatriptan

Criteria

Inclusion Criteria:

• Greater than one year history of migraine

• Attacks typically mild when they begin and progress to moderate or severe

• Experience 1-4 migraine attacks per month

Exclusion Criteria:

• More than 15 headache days per month

• Heart disease

• Uncontrolled high blood pressure